This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Dermatologic Disorders  • Alopecia  • Hair Disorders  • Dermatologic Disorders, Other  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Lori A. Spencer, MD, PhD; Elena Balestreire Hawryluk, PhD; Joseph C. English III, MD

Arch Dermatol. 2009;145(3):333-334.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Lichen planopilaris (LPP) is a primary lymphocytic scarring alopecia that causes inflammation, erythema, pruritus, dysesthesia, and alopecia that can be treatment resistant. After approval from the institutional review board, we performed a retrospective case analysis of alopecia due to LPP to assess possible therapeutic effectiveness.

Methods

All medical charts with International Classification of Diseases, Ninth Revision (ICD-9) diagnoses of alopecia (2004-2007) were analyzed: 674 cases were nonscarring (81%), and 159 were scarring alopecia (19%). Based on clinicopathologic correlation, LPP was diagnosed in 45 cases (28% scarring alopecia, 5% overall), and all patients were diagnosed by the same observer (J.C.E.). According to the criteria of the North American Hair Research Society,¹ histologic evidence of lymphocytic scarring inflammation includes lupus erythematosus (LE), classic pseudopelade, central centrifugal cicatricial alopecia, alopecia mucinosa, keratosis follicularis spinulosa decalvans, and LPP.¹

Lichen planopilaris and . . . [Full Text of this Article]

Results

Comment

AUTHOR INFORMATION


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?